研究单位：[1]The Third Affiliated Hospital of Southern Medical University[2]Xuanwu Hospital,Beijing[3]Qilu Hospital of Shandong University[4]The First Affiliated Hospital of Kunming Medical College[5]First Affiliated Hospital of Xinjiang Medical University[6]Second Affiliated Hospital of Third Military Medical University[7]Henan Provincial People's Hospital[8]The Second Hospital University of South China[9]Shenzhen Second People's Hospital[10]People's Hospital of Guangxi[11]Department of Biostatistics,Southern Medical University[12]LanZhou University[13]The First Affiliated Hospital of HuNan University of Medicine[14]Guangdong 999 Brain Hospital[15]Maoming People's Hospital[16]The Fifth Affiliated Hospital of Southern Medical University[17]Zhongshan People's Hospital,Guangdong,China[18]Fifth Affiliated Hospital,Sun Yat-Sen University
研究目的：
This study evaluates safety and efficacy of analgesia-first minimal sedation as an early antihypertensive treatment for spontaneous intracerebral hemorrhage. The analgesia-first minimal sedation strategy relies on the remifentanil-mediated alleviation of pain-induced stress response and the antisympathetic activity of dexmedetomidine to restore the elevated blood pressure to normal level in patients with spontaneous intracerebral hemorrhage. This strategy allows rapid stabilization of blood pressure, and its use as a pre-treatment for patients on mechanical ventilation prior to painful procedures reduces blood pressure variability and thereby results in etiologic treatment. It is more effective in blood pressure control than conventional symptomatic antihypertensive treatment, reduces the incidence of early hematoma expansion and improves prognosis, ,lowers healthcare workers workload, increases patient adherence, and improves healthcare worker satisfaction.
